TissGeneSummary for PRR23B |
Gene summary |
Basic gene information | Gene symbol | PRR23B |
Gene name | proline rich 23B | |
Synonyms | - | |
Cytomap | UCSC genome browser: 3q23 | |
Type of gene | protein-coding | |
RefGenes | NM_001013650.2, | |
Description | proline-rich protein 23B | |
Modification date | 20141207 | |
dbXrefs | HGNC : HGNC | |
Ensembl : ENSG00000184814 | ||
HPRD : 18392 | ||
Vega : OTTHUMG00000160633 | ||
Protein | UniProt: go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_PRR23B | |
BioGPS: 389151 | ||
Pathway | NCI Pathway Interaction Database: PRR23B | |
KEGG: PRR23B | ||
REACTOME: PRR23B | ||
Pathway Commons: PRR23B | ||
Context | iHOP: PRR23B | |
ligand binding site mutation search in PubMed: PRR23B | ||
UCL Cancer Institute: PRR23B | ||
Assigned class in TissGDB* | C | |
Included tissue-specific gene expression resources | HPA,GTEx | |
Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | Testis | |
Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | TGCT | |
Reference showing the relevant tissue of PRR23B | ||
Description by TissGene annotations | TissgsKTS CNV lost TissGeneKTS |
* Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO term | PubMed ID |
Top |
TissGeneExp for PRR23B |
Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
- Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
Top |
TissGene-miRNA for PRR23B |
Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
Top |
TissGeneMut for PRR23B |
TissGeneSNV for PRR23B |
nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
- nsSNVs sorted by frequency. |
AAchange | Cancer type | # samples |
p.E110K | SKCM | 2 |
p.P251S | SKCM | 2 |
p.R220C | SKCM | 2 |
p.G173S | STAD | 2 |
p.D169N | SKCM | 2 |
p.G93S | SKCM | 1 |
p.D109G | CESC | 1 |
p.A114V | STAD | 1 |
p.V136I | GBM | 1 |
p.P8H | LUAD | 1 |
p.G243S | BLCA | 1 |
p.D51N | SKCM | 1 |
p.A53V | SKCM | 1 |
p.A246T | UCEC | 1 |
p.R167L | LIHC | 1 |
p.E162D | LUAD | 1 |
p.D74E | BLCA | 1 |
p.V136I | BRCA | 1 |
p.L122P | STAD | 1 |
p.H245Q | LUAD | 1 |
p.E252D | STAD | 1 |
p.R220H | BRCA | 1 |
p.P146L | SKCM | 1 |
p.G93D | SKCM | 1 |
p.P211S | SKCM | 1 |
p.Y155X | KIRP | 1 |
p.P197L | SKCM | 1 |
p.A65T | STAD | 1 |
p.G94E | SKCM | 1 |
p.P84L | SKCM | 1 |
p.E140K | SKCM | 1 |
p.S118L | GBM | 1 |
p.R6C | KIRC | 1 |
p.R167W | HNSC | 1 |
p.A143T | LUSC | 1 |
p.S205I | LUSC | 1 |
p.R70P | HNSC | 1 |
p.G121V | LUSC | 1 |
p.P188S | SKCM | 1 |
p.R190Q | LUAD | 1 |
p.A130T | SKCM | 1 |
p.L73V | UCS | 1 |
p.D125Y | LUSC | 1 |
p.G121V | LUAD | 1 |
p.S181F | SKCM | 1 |
p.R167Q | LUSC | 1 |
p.P254L | LUSC | 1 |
p.P195S | SKCM | 1 |
p.E138K | UCEC | 1 |
p.R183T | LGG | 1 |
p.E152K | SKCM | 1 |
p.P244T | HNSC | 1 |
p.G173D | SKCM | 1 |
p.P235S | SKCM | 1 |
p.R220C | LGG | 1 |
p.I60T | LUSC | 1 |
p.P249L | BLCA | 1 |
p.R247C | BLCA | 1 |
p.R167Q | PRAD | 1 |
p.S91F | SKCM | 1 |
p.Q151L | HNSC | 1 |
p.S210Y | BLCA | 1 |
p.G93S | STAD | 1 |
p.D55E | COAD | 1 |
p.L122Q | LUSC | 1 |
p.E153K | BLCA | 1 |
p.S86L | UCEC | 1 |
p.A149G | LGG | 1 |
p.E138V | LUSC | 1 |
p.P146S | SKCM | 1 |
p.R247H | LGG | 1 |
p.L250F | SKCM | 1 |
p.L57F | COAD | 1 |
p.R259W | SKCM | 1 |
p.P255L | SKCM | 1 |
p.R209C | MESO | 1 |
p.R167L | SKCM | 1 |
p.M168I | SKCM | 1 |
p.E156K | UCEC | 1 |
Top |
TissGeneCNV for PRR23B |
Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
Top |
TissGeneFusions for PRR23B |
Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
Top |
TissGeneNet for PRR23B |
Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
Top |
TissGeneProg for PRR23B |
Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Top |
TissGeneClin for PRR23B |
TissGeneDrug for PRR23B |
Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
TissGeneDisease for PRR23B |
Disease information associated with TissGene (DisGeNet, 2016-06-01) |
Disease ID | Disease name | # pubmeds | Source |